SCOTUS challenges on Teva patent case

U.S. Supreme Court justices on Wednesday voiced skepticism about arguments from both sides in the petition by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to overturn an appeals court decision that invalidated the company's process patent for multiple sclerosis blockbuster drug Copaxone glatiramer acetate.

The high court will decide whether the U.S. Court of Appeals for the Federal Circuit (CAFC) overreached by reviewing de novo certain questions of fact in Teva's lawsuit against the Sandoz International GmbH generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), rather than deferring to the findings of the U.S. District Court for the Southern District of New York. ...